Compare ETS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETS | KALA |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 13.3M |
| IPO Year | 2025 | 2017 |
| Metric | ETS | KALA |
|---|---|---|
| Price | $1.61 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | ★ 393.4K | 361.0K |
| Earning Date | 04-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,665,948.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.57 | N/A |
| 52 Week Low | $0.39 | $0.07 |
| 52 Week High | $1.55 | $20.58 |
| Indicator | ETS | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 76.21 | 34.86 |
| Support Level | $0.47 | $0.54 |
| Resistance Level | N/A | $0.72 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 99.83 | 14.43 |
Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.